We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App





Ortho Exhibits High Quality, Accurate and Cost Effective COVID19 Testing Solutions at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Illustration
Illustration

Ortho Clinical Diagnostics (Raritan, NJ, USA) exhibited its range of high quality, accurate and cost effective COVID19 testing solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held at the Georgia World Congress Center in Atlanta, September 26-30.

Over the span of the four day event, attendees connected with global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine.

Ortho has been at the forefront of developing high quality, accurate, cost effective COVID19 testing solutions that run at high volumes. At AACC 2021, Ortho demonstrated its high-throughput testing solutions for SARS-CoV-2 infection, antibody detection and antigen detection. These included the high-throughput, highly accurate VITROS SARS-CoV-2 antigen test that detects acute infection of SARS-CoV-2. The test delivers fast, high-volume testing for active infection with excellent specificity and sensitivity, making it a viable alternative to PCR testing.

In addition, Ortho highlighted its three qualitative antibody tests, including the VITROS COVID-19 Total and IgG antibody assays that provide highly accurate and reliable detection of SARS-CoV-2 antibodies to help clinicians and researchers understand immune response; and its VITROS Anti-SARS-CoV-2 Total N antibody test that is designed to capture total antibodies to the nucleocapsid protein. Also on display at AACC 2021 was the VITROS Anti-SARS-CoV-2 IgG quantitative test that helps labs to quantify the level of COVID-19 antibodies for patients and individuals in their communities. The VITROS Anti-SARS-CoV-2 IgG quantitative test is the first quantitative test to receive U.S. Food and Drug Administration (FDA) EUA. Ortho also demonstrated its VITROS Performance Dashboard that allows labs to view productivity data from Ortho analyzers including: test volumes, positivity rates, quality and efficiency information to help make more informed decisions for the hospital and community.

Related Links:
Ortho Clinical Diagnostics 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS-CoV-2 Test
One Step SARS-CoV-2 Nucleic Acid Detection Kit (P761H)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.